ReviewJournal of biomedical science2013
Current progress in dengue vaccines.
Review in Journal of biomedical science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials.PLoS neglected tropical diseases · 2016Trial
- Multi-epitope vaccine candidate design for dengue virus.Bioinformation · 2023Article
- Controlled Human Infection Models To Accelerate Vaccine Development.Clinical microbiology reviews · 2022Review
- Morphological Aspects and Viremia Analysis of BALB/c Murine Model Experimentally Infected with Dengue Virus Serotype 4.Viruses · 2021Article
- Investigation on the Occurrence ofJournal of arthropod-borne diseases · 2019Article
- Designing a polytope for use in a broad-spectrum dengue virus vaccine.Journal of Taibah University Medical Sciences · 2018Article
- In silico prediction of monovalent and chimeric tetravalent vaccines for prevention and treatment of dengue fever.Journal of biomedical research · 2017Article
- Antibodies Against Modified NS1 Wing Domain Peptide Protect Against Dengue Virus Infection.Scientific reports · 2017Article
- Adult-onset, chronic, cyclic thrombocytopenia in a Rhesus macaque (Macaca mulatta) after dengue virus vaccination and viral challenge.Veterinary clinical pathology · 2017Article
- Cyclooxygenase-2 facilitates dengue virus replication and serves as a potential target for developing antiviral agents.Scientific reports · 2017Article
- Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses.PLoS neglected tropical diseases · 2016Article
- DengueME: A Tool for the Modeling and Simulation of Dengue Spatiotemporal Dynamics.International journal of environmental research and public health · 2016Review
- Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.Human vaccines & immunotherapeutics · 2016Article
- Recent advances in the production of recombinant subunit vaccines in Pichia pastoris.Bioengineered · 2016Review
- Computational analysis of perturbations in the post-fusion Dengue virus envelope protein highlights known epitopes and conserved residues in the Zika virus.F1000Research · 2016Article
- Dengue Fever: Causes, Complications, and Vaccine Strategies.Journal of immunology research · 2016Review
- In Silico Screening, Alanine Mutation, and DFT Approaches for Identification of NS2B/NS3 Protease Inhibitors.Biochemistry research international · 2016Article
- Article
- Dengue epidemiology and pathogenesis: images of the future viewed through a mirror of the past.Virologica Sinica · 2015Review
- Correlation between serum levels of anti-endothelial cell autoantigen and anti-dengue virus nonstructural protein 1 antibodies in dengue patients.The American journal of tropical medicine and hygiene · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.